Adaptive Biotechnologies Third Quarter Financial Results - ADAPTIVE BIOTECHNOLOGIES CORP

Financial Performance:

• Total revenue reached $83.9 million, a 39% year-over-year increase driven by MRD growth and a Pfizer milestone.
• MRD revenue was $72.6 million (86% of total), growing 28% year-over-year; excluding milestones, core MRD revenue grew 44%.
• The company achieved total company profitability with GAAP net income of $2.8 million and positive Adjusted EBITDA of $14.3 million.
• Gross margin for total company reached 76%; MRD sequencing gross margin was 74% and overall sequencing gross margin (excluding milestones) increased to 73%.
• Generated $8 million in free cash flow and ended Q3 2026 with $386 million in total cash.
• Operating expenses were $84.4 million, up only 1% year-over-year, reflecting disciplined spending despite commercial investments.

Guidance and Future Outlook:

• Full-year 2026 MRD revenue guidance was raised to $276–$286 million (previously $268–$278 million), implying 41% growth excluding milestones.
• Full-year clinical volume growth is now expected at approximately 42% (previously 38–40%).
• Full-year operating expenses are expected at approximately $350 million.
• Management anticipates sustained high growth into 2027 and beyond, targeting a long-term ASP of $1,700–$1,800 per test.
• No GAAP net income or positive EPS is currently anticipated for Q4 or the full year 2026.
• Future revenue is expected to be driven by reimbursement expansions, increased testing frequency, and new indications.

Business Segments and Product Lines:

• ClonoSeq (MRD): Clinical testing volume grew 46% year-over-year; nearly 40,000 tests delivered (up 10% sequentially).
  • Blood-based testing surged 68% year-over-year, now comprising 51% of total volume; 31% of myeloma testing is now blood-based.
  • Community practice volume grew 14% sequentially, now representing 37% of total volume.
  • CLB (DLBCL) and Multiple Myeloma led growth; DLBCL volume grew 20% sequentially.
• Pharma Sequencing: Revenue grew 55% year-over-year; backlog reached $270 million (up 34%), with 60% of active studies in multiple myeloma.
• Immune Medicine: Revenue was $11.3 million, primarily from a Pfizer rheumatoid arthritis milestone; working with Morgan Stanley to advance separation process.

Market and Competitive Landscape:

• Guidelines & Definition of Cure: Updated NCCN guidelines explicitly recommend ClonoSeq and 10^-6 sensitivity; a new International Myeloma Working Group "definition of cure" requires 10^-6 NGS testing, favoring ClonoSeq as the sole assay capable of this scale.
• Regulatory Tailwinds: FDA draft guidance supports MRD as an accelerated endpoint in drug development; 19 multiple myeloma studies now use MRD as a primary endpoint.
• Reimbursement: Expanded commercial coverage in DLBCL and MCL; Medicaid coverage now spans 62% of testing volume; Medicare Advantage is the largest growth opportunity.
• Competition: Management views competitor noise as beneficial for market education, emphasizing ClonoSeq's established moat, reimbursement, and clinical data.

Risks and Challenges:

• Medicare Reimbursement: Current Medicare episodic billing (bundle of four tests) pressures ASP as testing frequency increases; management is actively negotiating a "maintenance bundle" with Molina.
• PAMA/Labs: CMS draft rates for 2027 contained erroneous data for ClonoSeq's PLA code; management is working to correct this before finalization in November.
• Revenue Timing: Pharma milestones are lumpy and unpredictable; Q4 full-year GAAP income remains negative.
• Adoption Friction: Continued effort required to integrate EMR and ensure serial monitoring compliance across community and academic settings.

Management Commentary and Tone:

• Tone was highly confident and optimistic, characterizing Q3 as a "breakthrough quarter" marking a sustainable growth and profitability inflection point.
• Management emphasized that profitability enables reinvestment into competitive moats (AI, real-world data, next-gen products).
• Executive leadership expressed strong conviction in the 2027 growth trajectory, citing the convergence of clinical guidelines and commercial execution.

Analyst Questions and Answers:

• CMS Rates: Confirmed engagement with CMS to rectify erroneous PLA data; do not expect PAMA rates to impact episodic Medicare billing.
• Growth Drivers for 2027: Expected to be a combination of guideline pull-through, blood-based testing expansion, EMR optimization, and community adoption.
• DLBCL Strength: Growth attributed to broad adoption in community networks and education on MRD's role vs. PET scans; expected to remain a top driver.
• Pharma Backlog: $270M backlog supports 25% growth rate; future milestones are expected but timing remains variable.
• Capital Deployment: Profits will be reinvested into R&D, AI/automation, real-world data, and new immunosequencing applications beyond hematology.
• ASP Trajectory: Current $1,380 ASP is a step toward $1,400 for the year; long-term $1,700–$1,800 target remains on track, supported by the upcoming maintenance bundle discussions with Molina.

Other Key Points:

• ClonoSeq is the only assay capable of 10^-6 sensitivity at the required scale for broad clinical use and the new "cure" definition.
• EMR integrations (e.g., Flatiron) show high follow-through on serial monitoring orders (78% fulfillment rate).
• The company is exploring new applications of its immunosequencing platform beyond hematology.
• Active discussions with Molina regarding a 5-test maintenance bundle in multiple myeloma are viewed as a high-probability catalyst for ASP expansion.